18.7 C
New York
Saturday, June 3, 2023

What Are The Chances Of Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Ionis Pharmaceuticals Inc. (IONS) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.79, or -2.22%, to $34.72. The Ionis Pharmaceuticals Inc. has recorded 15,208 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Ionis to host 2023 virtual Annual Meeting of Stockholders.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.

Sponsored

Stocks Info

As a NASDAQ listed company, IONS falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $35.51 and fluctuated between $35.76 as its day high and $35.36 as its day low. The current market capitalization of Ionis Pharmaceuticals Inc. is $5.09B. A total of 0.58 million shares were traded on the day, compared to an average of 902.20K shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, IONS has seen 8 BUY and 3 SELL insider trades, representing the acquisition of 20,377 and the disposition of 7,134 shares. Over the last 12 months, there were 52 BUYs and 28 SELLs from insiders. Insiders purchased 379,319 shares during that period but sold 127,673.

In the most recent transaction, Baroldi Joseph sold 3,880 shares of IONS for 36.50 per share on Apr 18. After the transaction, the EVP, Chief Business Officer now owns 10,571 company shares. In a previous transaction on Apr 18, Cadoret-Manier Onaiza sold 2,582 shares at 36.50 per share. IONS shares that EVP, Chf GL Pdt Str & Oper Ofc owns now total 24,312.

Among the insiders who sold shares, Birchler Brian disposed of 672 shares on Apr 18 at a per-share price of $36.50. This resulted in the EVP, Corp and Development Ops holding 36,528 shares of IONS after the transaction. In another insider transaction, Monia Brett P sold 24,651 shares at $40.69 per share on Feb 06. Company shares held by the Chief Executive Officer now total 145,305.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for IONS in the last 3 months, the mean price target is $48.96 with high estimates of $88.00 and low estimates of $26.00. In terms of 52-week highs and lows, IONS has a high of $48.82 and a low of $32.62.

As of this writing, IONS has an earnings estimate of -$0.89 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of -$0.71 per share and a lower estimate of -$1.07. The company reported an EPS of -$0.37 in the last quarter, which was 59.80% higher than expectations of -$0.92.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. IONS’s latest balance sheet shows that the firm has $2.12B in Cash & Short Term Investments as of fiscal 2021. There were $1.16B in debt and $241.00M in liabilities at the time. Its Book Value Per Share was $3.41, while its Total Shareholder’s Equity was $772.00M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Buy with a score of 3.50.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles